Patents Issued in April 21, 2020
  • Patent number: 10626393
    Abstract: The present invention provides lipid particles comprising therapeutic nucleic acids such as gRNA that target gene expression.
    Type: Grant
    Filed: June 6, 2016
    Date of Patent: April 21, 2020
    Assignee: ARBUTUS BIOPHARMA CORPORATION
    Inventors: Amy C. H. Lee, Nicholas D. Weber
  • Patent number: 10626394
    Abstract: Disclosed herein are novel synthetic bacteriophages and bacteriophage compositions, methods of production thereof, and therapeutic uses thereof.
    Type: Grant
    Filed: October 27, 2017
    Date of Patent: April 21, 2020
    Assignee: Massachusetts Institute of Technology
    Inventors: Timothy Kuan-Ta Lu, Sebastien Lemire, Andrew C. Yang, Kevin M. Yehl
  • Patent number: 10626395
    Abstract: Methods of treating Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD), comprising administering an inhibitory nucleic acid that targets miR-128.
    Type: Grant
    Filed: September 18, 2017
    Date of Patent: April 21, 2020
    Assignees: The General Hospital Corporation, Aalborg University
    Inventors: Anders M. Naar, Sakari Kauppinen, Andreas Petri
  • Patent number: 10626396
    Abstract: A method and compound for treating skeletal muscle mass deficiency in a human subject are disclosed. The composition is an oligomer of morpholino subunits and phosphorus-containing intersubunit linkages joining a morpholino nitrogen of one subunit to a 5? exocyclic carbon of an adjacent subunit, contains between 10-40 nucleotide bases, has a base sequence effective to hybridize to an expression-sensitive region of processed or preprocessed human myostatin RNA transcript, identified, in its processed form, by SEQ ID NO:6, and is capable of uptake by target muscle cells in the subject. In practicing the method, the compound is administered in an amount and at a dosage schedule to produce an overall reduction in the level of serum myostatin measured in the patient, and preferably to bring the myostatin level within the a range determined for normal, healthy individuals.
    Type: Grant
    Filed: May 22, 2018
    Date of Patent: April 21, 2020
    Assignee: Sarepta Therapeutics, Inc.
    Inventors: Patrick L. Iversen, Dwight D. Weller, Alan P. Timmins
  • Patent number: 10626397
    Abstract: A method of inhibiting the growth of cancer stem cells, including administering an effective amount of a protein kinase D1 expression or activity inhibitor as an active ingredient to a subject having cancer is provided. Further, a method of treating cancer, including administering an effective amount of a protein kinase D1 expression or activity inhibitor, and antitumor agent as active ingredients to a subject having cancer is provided. Further, a method for measuring expression or activity of protein kinase D1 for providing information of breast cancer prognosis, including a step of measuring expression or activity of protein kinase D1 in cells or tissues isolated from a subject is provided.
    Type: Grant
    Filed: June 8, 2017
    Date of Patent: April 21, 2020
    Assignee: SOOKMYUNG WOMEN'S UNIVERSITY INDUSTRY ACADEMIC COOPERATION FOUNDATION
    Inventors: Jong Hoon Park, Do Yeon Kim, Eun Young Park, Kyung-Hee Chun, Eun Ji Lee, Eun Sun Chang, Hyeok-Gu Kang
  • Patent number: 10626398
    Abstract: The oligonucleotide compositions of the present invention make use of combinations of oligonucleotides. In one aspect, the invention features an oligonucleotide composition including at least 2 different oligonucleotides targeted to a target gene. This invention also provides methods of inhibiting protein synthesis in a cell and methods of identifying oligonucleotide compositions that inhibit synthesis of a protein in a cell.
    Type: Grant
    Filed: January 21, 2019
    Date of Patent: April 21, 2020
    Assignee: LIFE TECHNOLOGIES CORPORATION
    Inventors: Tod Woolf, Margaret Taylor
  • Patent number: 10626399
    Abstract: Methods of treating an adult mammal for an aging-associated impairment are provided. Aspects of the methods include modulating CCR3, e.g., by modulating eotaxin-1/CCR3 interaction, in the mammal in a manner sufficient to treat the mammal for the aging-associated impairment. A variety of aging-associated impairments may be treated by practice of the methods, which impairments include cognitive impairments.
    Type: Grant
    Filed: January 6, 2017
    Date of Patent: April 21, 2020
    Assignees: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY, THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS
    Inventors: Anton Wyss-Coray, Thomas A. Rando, Markus Britschgi, Kaspar Rufibach, Saul A. Villeda
  • Patent number: 10626400
    Abstract: The present invention relates to stable low-salt aqueous formulations of particles comprising a polycation, preferably protamine, and RNA, which formulations are preferably isotonic, to pharmaceutical compositions or kits comprising such formulations and to their use in medicine. It further relates to methods for preparing the formulations of the invention and to methods for physically stabilizing particles comprising a polycation, preferably protamine, and RNA.
    Type: Grant
    Filed: July 4, 2014
    Date of Patent: April 21, 2020
    Assignee: BioNTech AG
    Inventor: Steve Pascolo
  • Patent number: 10626401
    Abstract: The invention relates to non-CpG single-stranded oligonucleotides (ssONs) for use in the treatment or prophylaxis of disorders of the skin and/or subcutaneous tissue, including pruritus, in a suitable formulation or in combination with other immunomodulatory treatments. The said ssONs have a length of at least 25 nucleotides and are stabilized by phosphorothioate internucleotide linkages and/or 2?-O-Methyl modifications.
    Type: Grant
    Filed: June 14, 2016
    Date of Patent: April 21, 2020
    Assignee: TIRMED PHARMA AB
    Inventors: Anna-Lena Spetz, Peter Jarver, Annette Skold
  • Patent number: 10626402
    Abstract: Methods are provided herein for assembling at least two nucleic acids using a sequence specific nuclease agent (e.g., a gRNA-Cas complex) to create end sequences having complementarity and subsequently assembling the overlapping complementary sequences. The nuclease agent (e.g., a gRNA-Cas complex) can create double strand breaks in dsDNA in order to create overlapping end sequences or can create nicks on each strand to produce complementary overhanging end sequences. Assembly using the method described herein can assemble any nucleic acids having overlapping sequences or can use a joiner oligo to assemble sequences without complementary ends.
    Type: Grant
    Filed: March 7, 2019
    Date of Patent: April 21, 2020
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Chris Schoenherr, John McWhirter, Corey Momont, Caitlin L. Goshert, Lynn MacDonald, Gregg S. Warshaw, Jose F. Rojas, Ka-Man Venus Lai, David M. Valenzuela, Andrew J. Murphy
  • Patent number: 10626403
    Abstract: A live bacterium, having a DNA construct stabilized against transduction of other bacteria, having a promoter sequence and encoding a fusion peptide, comprising a bacterial secretion peptide portion and a non-bacterial immunogenic polypeptide portion, having a nucleotide sequence coding for the non-bacterial immunogenic polypeptide portion which has at least one codon optimized for bacterial expression. The bacterium has a secretion mechanism which interacts with at least the bacterial secretion peptide portion to cause a secretion of the fusion peptide from the bacterium, and a genetic virulence attenuating mutation. The bacterium is adapted to act as an animal vaccine, to transiently infect a tissue of the animal, and cause an immunity response to the non-bacterial immunogenic polypeptide portion in the animal to a non-bacterial organism associated with the non-bacterial immunogenic polypeptide portion.
    Type: Grant
    Filed: October 1, 2018
    Date of Patent: April 21, 2020
    Assignee: Aviex Textnologies LLC
    Inventor: David Gordon Bermudes
  • Patent number: 10626404
    Abstract: The present invention provides information on a mutant xylose isomerase gene and a mutant protein with which it is possible to impart high xylose metabolic capacity to budding yeast. Also provided is a yeast strain having the mutant xylose isomerase gene. Additionally provided is an efficient method for producing a useful substance using the yeast strain. The present invention provides mutant Clostridium-phytofermentans-derived xylose isomerase (CpXI) having high xylose metabolic activity, the CpXI comprising an amino acid sequence corresponding to an amino acid sequence in which the number 63 threonine of SEQ ID NO: 11 of CpXI is substituted by isoleucine, leucine, glycine, or histidine and/or the number 162 valine is substituted by alanine.
    Type: Grant
    Filed: March 24, 2017
    Date of Patent: April 21, 2020
    Assignee: National Institute of Advanced Industrial Science and Technology
    Inventors: Taisuke Seike, Kazuhiro Fujimori, Yosuke Kobayashi, Takehiko Sahara, Satoru Ohgiya, Yoichi Kamagata
  • Patent number: 10626405
    Abstract: To provide a base sequence for protein expression that can increase the yield of protein such as diastatic enzyme by further activating a promoter of a particular gene. A base sequence 1 for protein expression includes: a gene 3 encoding protein 2; a promoter 4 of the gene 3, the promoter being linked upstream of the gene 3; and a cis element 5 whose activity is improved by an artificial transcription factor 6, the cis element being linked further upstream of the promoter 4. The cis element 5 is represented by SEQ ID NO: 1.
    Type: Grant
    Filed: July 15, 2016
    Date of Patent: April 21, 2020
    Assignee: Honda Motor Co., Ltd.
    Inventors: Satoru Shinkawa, Shigenobu Mitsuzawa, Maiko Tanaka, Masayuki Machida, Hiroko Hagiwara, Hideaki Koike, Mahoko Kuninaga
  • Patent number: 10626406
    Abstract: The invention relates to the field of plant improvement, in particular of the improvement of yield for plants, by using a transgene containing an root-specific promoter driving expression of a MYB-related protein.
    Type: Grant
    Filed: July 29, 2016
    Date of Patent: April 21, 2020
    Assignee: GENOPLANTE-VALOR
    Inventors: François Torney, Jérôme Martin, Stéphane Lafarge
  • Patent number: 10626407
    Abstract: A method of modifying the amount of at least one biochemical component in a plant comprising expressing Qua-Quine Starch (QQS) in the plant, the wild-type of which does not express QQS; a transgenic plant, or part thereof, which comprises and expresses QQS as a transgene and in which the amount of at least one biochemical component is modified; a tissue culture of regenerable cells of the transgenic plant; a vector comprising a nucleotide sequence, which encodes the coding sequence of QQS, operably linked to a non-native promoter, which promotes expression of the nucleotide sequence in a plant, which is other than Arabidopsis; and a method of producing a food or industrial product from a plant.
    Type: Grant
    Filed: November 21, 2017
    Date of Patent: April 21, 2020
    Assignee: Iowa State University Research Foundation, Inc.
    Inventors: Ling Li, Eve Syrkin Wurtele
  • Patent number: 10626408
    Abstract: A method of producing collagen in a plant and plants producing collagen are provided. The method is effected by expressing in the plant at least one type of a collagen alpha chain in a manner enabling accumulation of the collagen alpha chain in a subcellular compartment devoid of endogenous P4H activity, thereby producing the collagen in the plant.
    Type: Grant
    Filed: October 3, 2017
    Date of Patent: April 21, 2020
    Assignee: CollPlant Ltd.
    Inventors: Oded Shoseyov, Hanan Stein
  • Patent number: 10626409
    Abstract: Provided herein are genetic markers and a coding sequence associated with a low- or ultra-low anatabine trait in tobacco.
    Type: Grant
    Filed: July 8, 2015
    Date of Patent: April 21, 2020
    Assignee: ALTRIA CLIENT SERVICES LLC
    Inventors: Chengalrayan Kudithipudi, Alec J. Hayes, Robert Frank Hart, III, Yanxin Shen, Jesse Frederick, Dongmei Xu
  • Patent number: 10626410
    Abstract: Isolated polynucleotides and polypeptides, and recombinant DNA constructs useful for conferring improved nitrogen use efficiency and/or drought stress tolerance; compositions (such as plants or seeds) comprising these recombinant DNA constructs; and methods utilizing these recombinant DNA constructs are disclosed. The recombinant DNA constructs comprise a polynucleotide operably linked to a promoter that is functional in a plant, wherein said polynucleotides encode abiotic stress tolerance polypeptides.
    Type: Grant
    Filed: January 29, 2019
    Date of Patent: April 21, 2020
    Inventors: Guihua Lu, Yang Gao, Cong Li, Junhua Liu, Guanfan Mao, Wei Wang, Xiping Wang, Changgui Wang
  • Patent number: 10626411
    Abstract: The present disclosure relates to a gene sequence Cry1Ab/Cry1AcZM, an expression cassette containing the gene, an expression vector, a host cell and the use thereof in plant breeding. The protein encoded by an insect-resistant gene according to the disclosure can be expressed in a monocotyledonous plant and further used for culturing an insect-resistant transgenic monocotyledonous plant harboring transgenes Cry1Ab/Cry1AcZM. Bioassay tests prove that the modified and synthesized gene sequence Cry1Ab/Cry1AcZM and the expression product of the constructed vector according to the disclosure have a killing effect on lepidopteran pests.
    Type: Grant
    Filed: July 22, 2016
    Date of Patent: April 21, 2020
    Assignee: China National Seed Group Corporation, Ltd.
    Inventors: Bolin Liu, Chao Tan, Qianqian Yang, Jieting Xu, Qin Wen, Long Qiu, Chonglie Ma, Wanggen Zhang
  • Patent number: 10626412
    Abstract: A newly identified protein that is encoded by a polynucleotide sequence associated with cytoplasmic male sterility restorer activity (Rf3) is described. The cytoplasmic male sterility restorer gene can be inserted through breeding introgression into plant genomes to restore cytoplasmic male sterility in plants. Further applications of the newly identified polynucleotide sequence associated with cytoplasmic male sterility restorer activity include a mutation (rf3) which results in cytoplasmic male sterility. The cytoplasmic male sterility restorer gene can be inserted through breeding introgression into plant genomes to result in cytoplasmic male sterility in plants. Methods for detecting the cytoplasmic male sterility restorer (Rf3) and the cytoplasmic male sterility (rf3) gene sequences are further described.
    Type: Grant
    Filed: February 2, 2018
    Date of Patent: April 21, 2020
    Assignee: Dow AgroSciences LLC
    Inventors: Ruihua Ren, Bruce A. Nagel, Liang Ye, Yanxin Star Gao, Ryan Gibson, Sushmitha Paulraj, Tyler Mansfield, Jafar Mammadov, Siva P. Kumpatla, Steven A. Thompson
  • Patent number: 10626413
    Abstract: The present invention provides a nucleic acid vector referred to as pVec constructed through molecular biotechnologies. pVec contains CMV enhancer/promoter, T7 promoter, 5?UTR, MCS, 3?UTR, poly A (120A)-TTATT, BGH poly (A) signal, kanamycin resistance gene and pUC origin, etc. So pVec can be used as a vector for both DNA vaccines or therapeutic drugs and mRNA vaccines or mRNA therapeutic drugs. The 5?UTR, 3?UTR and poly A (120A)-TTATT of pVec can be added to the 5? and 3? ends of the in vitro transcribed mRNA respectively and further stabilize the transcribed mRNA. The present invention also provides the constructed pVec-GM-CSF, pVec-hIL-12 and pVAX1-hIL-12, which are used for evaluating the benefits of pVec.
    Type: Grant
    Filed: January 15, 2016
    Date of Patent: April 21, 2020
    Inventor: Enyu Ding
  • Patent number: 10626414
    Abstract: The present invention relates to Equine Herpes Virus (EHV) vectors comprising at least one exogenous antigen encoding sequence relating to a pathogen infecting food producing animals, wherein said exogenous antigen encoding sequence is inserted into an insertion site, preferably ORF70, and said exogenous antigen encoding sequence is operably linked to a promoter sequence, preferably the promoter sequence comprising 4pgG600 (SEQ ID NO:1) or 4pMCP600 (SEQ ID NO:2) or the complementary nucleotide sequences thereof or a functional fragment or a functional derivative thereof or the complementary nucleotide sequences thereof. Furthermore, the present invention relates to methods for immunizing a food producing animal comprising administering to such food producing animal an immunogenic composition comprising embodiments of the present invention. Moreover, the present invention relates to methods for the treatment or prophylaxis of clinical signs caused by swine influenza virus in a food producing animal.
    Type: Grant
    Filed: September 18, 2017
    Date of Patent: April 21, 2020
    Inventors: Andreas Gallei, Alice Mundt, Veljko Nikolin
  • Patent number: 10626415
    Abstract: A method of correcting singletons in a selected AAV sequence in order to increasing the packaging yield, transduction efficiency, and/or gene transfer efficiency of the selected AAV is provided. This method involves altering one or more singletons in the parental AAV capsid to conform the singleton to the amino acid in the corresponding position(s) of the aligned functional AAV capsid sequences.
    Type: Grant
    Filed: October 27, 2017
    Date of Patent: April 21, 2020
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Luk Vandenberghe, Guangping Gao, James M. Wilson
  • Patent number: 10626416
    Abstract: Disclosed herein are nucleic acid-guided nucleases, guide nucleic acids, and targetable nuclease systems, and methods of use. Disclosed herein are engineered non-naturally occurring nucleic acid-guided nucleases, guide nucleic acids, and targetable nuclease systems, and methods of use. Targetable nuclease systems can be used to edit genetic targets, including recursive genetic engineering and trackable genetic engineering methods.
    Type: Grant
    Filed: August 22, 2019
    Date of Patent: April 21, 2020
    Assignee: Inscripta, Inc.
    Inventors: Ryan T. Gill, Andrew Garst, Tanya Elizabeth Warnecke Lipscomb
  • Patent number: 10626417
    Abstract: A transgenic cat with a phenotype characterized by the substantial absence of the major cat allergen, Fel d I. The phenotype is conferred in the transgenic cat by disrupting the coding sequence of the target gene with a specialized construct. The phenotype of the transgenic cat is transmissible to its offspring.
    Type: Grant
    Filed: October 11, 2016
    Date of Patent: April 21, 2020
    Inventors: David B. Avner, James Kehler, Sven Bocklandt
  • Patent number: 10626418
    Abstract: Provided herein are methods of integrating one or more exogenous nucleic acids into one or more selected target sites of a host cell genome. In certain embodiments, the methods comprise contacting the host cell genome with one or more integration polynucleotides comprising an exogenous nucleic acid to be integrated into a genomic target site, a nuclease capable of causing a break at the genomic target site, and a linear nucleic acid capable of homologous recombination with itself or with one or more additional linear nucleic acids contacted with the population of cells, whereupon said homologous recombination results in formation of a circular extrachromosomal nucleic acid comprising a coding sequence for a selectable marker. In some embodiments, the methods further comprise selecting a host cell that expresses the selectable marker.
    Type: Grant
    Filed: July 24, 2018
    Date of Patent: April 21, 2020
    Assignee: AMYRIS, INC.
    Inventors: Andrew Horwitz, Kristy Michelle Hawkins, Max Schubert, Wayne Szeto
  • Patent number: 10626419
    Abstract: The present disclosure provides a DNA-targeting RNA that comprises a targeting sequence and, together with a modifying polypeptide, provides for site-specific modification of a target DNA and/or a polypeptide associated with the target DNA. The present disclosure further provides site-specific modifying polypeptides. The present disclosure further provides methods of site-specific modification of a target DNA and/or a polypeptide associated with the target DNA The present disclosure provides methods of modulating transcription of a target nucleic acid in a target cell, generally involving contacting the target nucleic acid with an enzymatically inactive Cas9 polypeptide and a DNA-targeting RNA. Kits and compositions for carrying out the methods are also provided. The present disclosure provides genetically modified cells that produce Cas9; and Cas9 transgenic non-human multicellular organisms.
    Type: Grant
    Filed: November 27, 2018
    Date of Patent: April 21, 2020
    Assignees: The Regents of the University of California, University of Vienna
    Inventors: Jennifer A. Doudna, Martin Jinek, Krzysztof Chylinski, Emmanuelle Charpentier
  • Patent number: 10626420
    Abstract: The invention features methods for producing isoprene from cultured cells. The invention also provides compositions that include these cultured cells.
    Type: Grant
    Filed: January 17, 2018
    Date of Patent: April 21, 2020
    Assignees: Danisco US Inc., The Goodyear Tire & Rubber Company
    Inventors: Marguerite A. Cervin, Gopal K. Chotani, Frank J. Feher, Richard La Duca, Joseph C. McAuliffe, Andrei Miasnikov, Caroline M. Peres, Aaron S. Puhala, Karl J. Sanford, Fernando Valle, Gregory M. Whited
  • Patent number: 10626421
    Abstract: The present invention relates to a method for cultivating in vitro in an acellular culture medium, bacteria for which the growth is sensitive to oxygen content, said bacterium being selected from anaerobic bacteria and intracellular micro-aerophilic bacteria, characterized in that uric acid is added into said acellular culture medium, and said bacterium is cultivated in said culture medium in the presence of oxygen.
    Type: Grant
    Filed: April 21, 2015
    Date of Patent: April 21, 2020
    Assignees: FONDATION MEDITERRANEE INFECTION FACULTÉ DE MÉDECINE, UNIVERSITE D'AIX MARSEILLE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE)
    Inventors: Didier Raoult, Saber Khelaifia, Michel Drancourt
  • Patent number: 10626422
    Abstract: Provided herein is a non-naturally occurring microbial organism having a methanol metabolic pathway (MMP) that can enhance the availability of reducing equivalents in the presence of methanol. Such reducing equivalents can be used to increase the product yield of organic compounds produced by the microbial organism, such as 1,4-butanediol (BDO). Also provided herein are methods for using such an organism to produce BDO.
    Type: Grant
    Filed: August 27, 2013
    Date of Patent: April 21, 2020
    Assignee: Genomatica, Inc.
    Inventors: Anthony P. Burgard, Robin E. Osterhout, Stephen J. Van Dien, Cara Ann Tracewell, Priti Pharkya, Stefan Andrae
  • Patent number: 10626423
    Abstract: A non-naturally occurring microorganism having a 1,3-BDO pathway is provided. The microorganism expresses at least one of the following 1,3-BDO pathway enzymes: an aldolase that catalyzes condensation of two acetaldehydes to produce 3-hydroxybutanal; and an aldo-ketoreductase, oxidoreductase, aldehyde reductase or alcohol dehydrogenase that reduces 3-hydroxybutanal to 1,3-BDO. The organism may further express one or more enzymes for producing acetaldehyde. A biosynthetic process involves condensing two acetaldehyde molecules to 3-hydroxybutanal using an enzyme from class aldolases; and selectively reducing 3-hydroxybutanal to 1,3-BDO using an enzyme belonging to the class aldo-ketoreductase, oxidoreductase, aldehyde reductase or alcohol dehydrogenase. The process can further include producing acetaldehyde by a biosynthetic method.
    Type: Grant
    Filed: July 21, 2016
    Date of Patent: April 21, 2020
    Assignee: THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO
    Inventors: Radhakrishnan Mahadevan, Alexander Yakunin, Pratish Gawand, Kayla Nemr
  • Patent number: 10626424
    Abstract: Recombinant microbial cells comprising an engineered LCDA production pathway that comprises at least one up-regulated long-chain acyl-CoA synthetase (ACoS) are disclosed. These recombinant microbial cells are capable of producing one or more long-chain dicarboxylic acid (LCDA) products from a long-chain fatty acid-comprising substrate. Methods of using recombinant microbial cells to produce LCDAs are also disclosed.
    Type: Grant
    Filed: July 20, 2016
    Date of Patent: April 21, 2020
    Assignee: DUPONT INDUSTRIAL BIOSCIENCES USA, LLC
    Inventors: Quinn Qun Zhu, Xiaochun Fan, Seung-Pyo Hong, Despina Boughioukou, Dongming Xie, Himanshu H. Dhamankar
  • Patent number: 10626425
    Abstract: The present invention relates to a microorganism for producing diamine, in which activity of a protein having an amino acid sequence of SEQ ID NO: 6 or an amino acid sequence having 55% or higher sequence homology with SEQ ID NO: 6 is introduced or enhanced, and a method of producing diamine using the same.
    Type: Grant
    Filed: January 4, 2019
    Date of Patent: April 21, 2020
    Assignee: CJ CHEILJEDANG CORPORATION
    Inventors: Kyoung Min Lee, Su Jin Park, Hee Kyoung Jung, Young Lyeol Yang, Hong Xian Li, Hye Won Um
  • Patent number: 10626426
    Abstract: The present invention relates to a microorganism of the genus Corynebacterium having an ability to produce L-arginine, and a method of producing L-arginine using the same.
    Type: Grant
    Filed: October 13, 2015
    Date of Patent: April 21, 2020
    Assignee: CJ CHEILJEDANG CORPORATION
    Inventors: Hyun Ae Bae, Han Hyoung Lee, Min Gyeong Kang, Jong Hyun Kim, Hye Won Kim
  • Patent number: 10626427
    Abstract: The present invention relates to a mutated protein of FMO derived from Celeribacter sp. and a gene encoding the same, a vector comprising the gene, a recombinant cell transformed by the vector, a composition for producing indigo comprising them, and a method for increasing indigo production in the recombinant cell using the transformed recombinant cell.
    Type: Grant
    Filed: April 22, 2019
    Date of Patent: April 21, 2020
    Assignee: GYEONGBUK INSTITUTE FOR MARINE BIOINDUSTRY
    Inventors: Jung Hee Woo, Hae Seon Kim, Nyun-Ho Park
  • Patent number: 10626428
    Abstract: The present invention relates to the field of poly- and oligosaccharides and their dietary effects. In particular it relates to a method of producing a branched ?-glucan. Further aspects of the invention are a branched ?-glucan comprising alternating ?(1?4) and ?(1?6) glucosidic linkages and having ?(1?4,6) branching points, a food composition, and the use of an ?-glucanotransferase enzyme for reducing the digestible carbohydrates of a starch containing food material.
    Type: Grant
    Filed: September 12, 2016
    Date of Patent: April 21, 2020
    Assignee: Societe des Produits Nestle S.A.
    Inventors: Joana Gangoiti Munecas, Sander Sebastiaan Van Leeuwen, Lubbert Dijkhuizen, Christina Vafeiadi, Lisa Lamothe
  • Patent number: 10626429
    Abstract: The present invention relates to methods of joining two or more double-stranded (ds) or single-stranded (ss) DNA molecules of interest in vitro, wherein the distal region of the first DNA molecule and the proximal region of the second DNA molecule of each pair share a region of sequence identity. The method allows the joining of a large number of DNA fragments, in a predetermined order and orientation, without the use of restriction enzymes. It can be used, e.g., to join synthetically produced sub-fragments of a gene or genome of interest. Kits for performing the method are also disclosed. The methods of joining DNA molecules may be used to generate combinatorial libraries useful to generate, for example, optimal protein expression through codon optimization, gene optimization, and pathway optimization.
    Type: Grant
    Filed: July 31, 2019
    Date of Patent: April 21, 2020
    Assignee: SGI-DNA, Inc.
    Inventors: Daniel G. Gibson, Hamilton O. Smith, Clyde A. Hutchison, Lei Young, J. Craig Venter
  • Patent number: 10626430
    Abstract: The present invention provides a method for preparing a mogroside having no ?-1,6-glucoside bond comprising the step of reacting glycosidase ASBGL2, AOBGL2, AOBGL1, ASBGL1, or a variant thereof with a mogroside having at least one ?-1,6-glucoside bond, thereby cleaving said ?-1,6-glucoside bond.
    Type: Grant
    Filed: January 19, 2016
    Date of Patent: April 21, 2020
    Assignee: SUNTORY HOLDINGS LIMITED
    Inventors: Misa Ochiai, Eiichiro Ono
  • Patent number: 10626431
    Abstract: The present invention provides a method for increasing the yield of a protein produced by cultivating eukaryotic cells and adding an ionic substance to the culture medium prior to harvest of the protein. Suitable ionic substances are the salts of the Hofmeister series, amino acids and peptone.
    Type: Grant
    Filed: June 30, 2016
    Date of Patent: April 21, 2020
    Assignee: OCTAPHARMA AG
    Inventor: Stefan Winge
  • Patent number: 10626432
    Abstract: A composition is provided. The composition comprises an enzyme and a ruthenium- or osmium-based electron transfer agent, wherein the ruthenium- or osmium-based electron transfer agent is a complex [M(A)x(B)y](X)n wherein M is ruthenium or osmium; A is an amine ligand; each B is a ligand different to A; x is an integer selected from 1 to 5; y is an integer selected from 1 to 5; x+y is 6 or 8; n is an integer selected from 1 to 6; and X is any suitable counterion.
    Type: Grant
    Filed: April 28, 2016
    Date of Patent: April 21, 2020
    Assignee: INSIDE BIOMETRICS INTERNATIONAL LIMITED
    Inventors: Marco Cardosi, Stephanie Kirkwood
  • Patent number: 10626433
    Abstract: The present invention provides members that produce on a large scale a coenzyme-linked glucose dehydrogenase which has excellent substrate-recognizing ability toward glucose while providing low action on maltose. The present invention relates to a polynucleotide encoding a soluble coenzyme-linked glucose dehydrogenase that catalyzes the oxidation of glucose in the presence of an electron acceptor and has an activity toward maltose of 5% or lower; a polypeptide encoded by the nucleotide sequence of the polynucleotide; a recombinant vector carrying the polynucleotide; a transformed cell produced using the recombinant vector; a method for producing a polypeptide comprising culturing the transformed cell and collecting from the cultivated products a polypeptide that links to FAD to exert the glucose dehydration activity; a method for determination of glucose using the polypeptide; a reagent composition for determination of glucose; and a biosensor.
    Type: Grant
    Filed: March 21, 2018
    Date of Patent: April 21, 2020
    Assignees: Ikeda Food Research Co., Ltd., PHC Corporation
    Inventors: Hironori Omura, Hirokazu Sanada, Takako Yada, Ayaka Atsumi, Tetsunari Morita, Emi Ishimaru
  • Patent number: 10626434
    Abstract: The present invention provides members that produce on a large scale a coenzyme-linked glucose dehydrogenase which has excellent substrate-recognizing ability toward glucose while providing low action on maltose. The present invention relates to a polynucleotide encoding a soluble coenzyme-linked glucose dehydrogenase that catalyzes the oxidation of glucose in the presence of an electron acceptor and has an activity toward maltose of 5% or lower; a polypeptide encoded by the nucleotide sequence of the polynucleotide; a recombinant vector carrying the polynucleotide; a transformed cell produced using the recombinant vector; a method for producing a polypeptide comprising culturing the transformed cell and collecting from the cultivated products a polypeptide that links to FAD to exert the glucose dehydration activity; a method for determination of glucose using the polypeptide; a reagent composition for determination of glucose; and a biosensor.
    Type: Grant
    Filed: September 28, 2018
    Date of Patent: April 21, 2020
    Assignees: Ikeda Food Research Co., Ltd., PHC Corporation
    Inventors: Hironori Omura, Hirokazu Sanada, Takako Yada, Ayaka Atsumi, Tetsunari Morita, Emi Ishimaru
  • Patent number: 10626435
    Abstract: Nanofluidic devices and methods of the invention are capable of autonomously isolating individual microbial cells using constrictive channels and growing monocultures of the cells for automated characterization of their biochemical properties and interactions with mammalian cells. Single microbial cells, such as bacterial cells, are isolated directly from environmental sources and cultured using chemical factors from their native environment.
    Type: Grant
    Filed: March 27, 2013
    Date of Patent: April 21, 2020
    Assignee: Northeastern University
    Inventors: Edgar Daniel Goluch, Yoshiteru Aoi, Slava Epstein
  • Patent number: 10626436
    Abstract: A method of determining variation between a query cell culture media and a reference cell culture media is provided. The method comprises the steps of incubating a reference cell with an aliquot of the query culture media and at least three chemical cell stressors in wells of a microtitre plate and determining an environmental response of the reference cell in the presence of the query cell culture media and each of the plurality of chemical cell stressors. A query cell culture media specific environmental response fingerprint is generated comprising the plurality of chemical cell stressor specific environmental responses. The query cell culture media-specific environmental response fingerprint is compared with a reference media-specific environmental response fingerprints corresponding to a reference cell culture media and generated using the reference cell.
    Type: Grant
    Filed: April 1, 2016
    Date of Patent: April 21, 2020
    Assignee: Valitacell Limited
    Inventors: Jerry Clifford, David James, Ben Thompson
  • Patent number: 10626437
    Abstract: The present invention is directed to a method and kit for inactivation of acid-fast bacteria. In some embodiments, the method may include: transferring a sample from a liquid culture containing acid-fast bacteria to a first tube, wherein the first tube comprises a body, a first end to the body having an opening, and a second end to the body having a frustoconical portion ending in a concave tip; centrifuging the tube to pellet the acid-fast bacteria in the concave tip and subsequently decanting a supernatant; resuspending the acid-fast bacteria pellet in alcohol; transferring the suspension to a second tube containing beads; agitating the second tube to disrupt acid-fast bacteria cells; and incubating the suspension to inactivate the acid-fast bacteria in the test sample. The method may also include identifying the acid-fast bacteria with mass spectrometry.
    Type: Grant
    Filed: July 15, 2016
    Date of Patent: April 21, 2020
    Assignee: bioMerieux, Inc.
    Inventors: Parampal Deol, Eric Miller, Erik Moreno, Heather Totty
  • Patent number: 10626438
    Abstract: The invention relates to a compound of Formula I: F1—X1-L1-X2—P1—X3-G1??(Formula I).
    Type: Grant
    Filed: December 5, 2017
    Date of Patent: April 21, 2020
    Assignee: The Broad Institute, Inc.
    Inventors: Yan-Ling Zhang, Edward Holson, Florence F. Wagner
  • Patent number: 10626439
    Abstract: The present invention provides, among other things, methods of quantitating mRNA capping efficiency, particularly mRNA synthesized in vitro. In some embodiments, methods according to the present invention comprise providing an mRNA sample containing capped and uncapped mRNA, providing a cap specific binding substance under conditions that permit the formation of a complex between the cap specific binding substance and the capped mRNA, and quantitatively determining the amount of the complex as compared to a control, thereby quantifying mRNA capping efficiency.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: April 21, 2020
    Assignee: Translate Bio, Inc.
    Inventors: Michael Heartlein, Frank DeRosa, Anusha Dias
  • Patent number: 10626440
    Abstract: A sequencer pretreatment device includes a suction and discharge mechanism, a nozzle head having a nozzle for mounting a dispensing tip, a container group for accommodating liquids including magnetic particle suspension, a moving mechanism for causing relative movement between the nozzle and the container group, and a magnetic unit that exerts a magnetic field to the mounted dispensing tip.
    Type: Grant
    Filed: May 21, 2014
    Date of Patent: April 21, 2020
    Assignee: UNIVERSAL BIO RESEARCH CO., LTD.
    Inventor: Hideji Tajima
  • Patent number: 10626441
    Abstract: Described herein is a method for adding a counter sequence to the individual polynucleotide molecules of an initial nucleic acid sample. After addition of the counter sequence, the sample may be amplified and the number of initial target molecules in the sample can be estimated by counting the number of counter sequences associated with the amplified target molecules.
    Type: Grant
    Filed: April 27, 2017
    Date of Patent: April 21, 2020
    Assignee: Agilent Technologies, Inc.
    Inventors: Robert Osborne, James Casbon, Andreas Claas, Gi Mikawa, Esther Musgrave-Brown
  • Patent number: 10626442
    Abstract: The invention provides methods, compositions, kits and devices for the detection of target molecules. In some embodiments, the invention allows for multiplexed target molecule detection.
    Type: Grant
    Filed: May 17, 2017
    Date of Patent: April 21, 2020
    Assignee: Roche Sequencing Solutions, Inc.
    Inventor: Garry P. Nolan